Lysozyme (Muramidase) Test

The Lysozyme (Muramidase) test is a specialized blood investigation that measures the concentration or activity of lysozyme in serum. Lysozyme is an antimicrobial enzyme produced by several types of immune cells and found naturally in tissues and secretions such as tears, saliva, mucus, and breast milk. In blood, it is associated particularly with neutrophils, monocytes, macrophages, and cells belonging to the myeloid immune system.

Lysozyme is also known as muramidase because it breaks specific chemical bonds within peptidoglycan, an important structural component of certain bacterial cell walls. This action contributes to innate immunity by damaging susceptible bacterial cell walls. The test does not measure general immune strength and is not a routine test for diagnosing bacterial infections.

Serum lysozyme may become elevated when the number or activity of monocytes and macrophages increases. This can occur in granulomatous inflammatory disorders such as sarcoidosis and tuberculosis and in selected haematological conditions, particularly leukaemias involving monocytic or myelomonocytic differentiation. It may also be affected by kidney function and other inflammatory or myeloproliferative conditions.

The Lysozyme test is not specific to one disease. An elevated result cannot independently diagnose sarcoidosis, tuberculosis, leukaemia, or another disorder. A normal result also cannot completely exclude these conditions. It should be interpreted with clinical symptoms, physical examination, blood counts, imaging, pathology, microbiology, kidney function, and other disease-specific investigations.

Benefits of the Lysozyme (Muramidase) Test

• Measures circulating lysozyme concentration or activity in a serum specimen.
• May support the assessment of patients with established or suspected sarcoidosis.
• Can contribute to the differential evaluation of selected myeloid leukaemias.
• May be elevated in disorders involving monocytic or myelomonocytic cell proliferation.
• Provides supplementary information in selected granulomatous inflammatory conditions.
• May assist monitoring in patients with a confirmed diagnosis when clinically appropriate.
• Can be interpreted with angiotensin-converting enzyme, imaging, and organ-specific tests in sarcoidosis.
• May complement complete blood count, peripheral smear, flow cytometry, and bone-marrow studies in haematology.
• Provides objective biochemical information for specialist interpretation.
• May help explain selected renal or electrolyte abnormalities associated with marked lysozyme production.

Clinical Indications and Applications

Sarcoidosis Evaluation: Sarcoidosis is an inflammatory disease characterised by the formation of non-caseating granulomas. It may affect the lungs, lymph nodes, skin, eyes, heart, nervous system, liver, or other organs. Activated macrophages within granulomas can release lysozyme, causing increased serum concentrations in some patients.

Serum lysozyme may be used as a supplementary marker in patients with proven or suspected sarcoidosis. It is not sufficiently specific to establish the diagnosis. Evaluation may also include chest imaging, pulmonary function testing, serum calcium, liver tests, eye examination, electrocardiography, angiotensin-converting enzyme measurement, biopsy, and tests to exclude infection or other granulomatous disorders.

Monitoring Established Sarcoidosis: In some patients with confirmed sarcoidosis and an initially elevated lysozyme value, serial measurements may contribute to monitoring. Changes do not always correspond directly to disease activity, organ involvement, or treatment response, so clinical and imaging findings remain essential.

Monocytic and Myelomonocytic Leukaemia: Lysozyme may be substantially elevated in leukaemias involving monocytic differentiation, including certain forms of acute myeloid leukaemia. The concentration may reflect the production of lysozyme by abnormal myeloid cells, but it cannot classify leukaemia independently.

Other Myeloid Disorders: Some myelogenous leukaemias and myeloproliferative conditions may be associated with increased lysozyme. Diagnosis requires a complete blood count, peripheral smear, bone-marrow examination, flow cytometry, cytogenetic testing, molecular studies, and specialist haematology interpretation.

Tuberculosis and Other Granulomatous Diseases: Lysozyme can rise in tuberculosis and other inflammatory conditions involving macrophage activation. The test cannot distinguish sarcoidosis from tuberculosis. Microbiological tests, imaging, tissue examination, culture, and molecular testing may be necessary.

Kidney and Electrolyte Assessment: Lysozyme is filtered by the kidneys and normally reabsorbed by proximal tubular cells. Very high lysozyme production, particularly in monocytic leukaemia, can exceed renal reabsorptive capacity and may contribute to tubular injury, urinary potassium loss, and hypokalemia. Kidney dysfunction can also affect circulating lysozyme levels.

Why Doctors Recommend This Test

Doctors recommend the Lysozyme test when it can provide supplementary information during the evaluation of granulomatous disease, an established sarcoidosis diagnosis, or a suspected myeloid or monocytic haematological disorder. It is usually requested by a pulmonologist, haematologist, rheumatologist, internal medicine physician, or another specialist.

In sarcoidosis, no single blood marker is sufficiently accurate to confirm or exclude the condition. Lysozyme may be elevated, but similar elevations can occur in infections, haematological disorders, kidney disease, and other inflammatory conditions. A tissue biopsy demonstrating compatible granulomas may be required while excluding alternative causes.

In suspected leukaemia, serum lysozyme provides only supplementary evidence. It does not identify the precise leukaemia subtype, genetic abnormality, prognosis, or treatment plan. Modern classification depends on morphology, immunophenotyping, cytogenetics, molecular testing, and clinical findings.

The test may also be used when a specialist is monitoring a patient whose lysozyme was previously elevated. For meaningful comparison, serial samples should ideally be measured using the same laboratory method and interpreted with the same clinical parameters.

Preparation Before the Test

Fasting is generally not required for the Lysozyme (Muramidase) test unless the sample is being collected with other tests that require fasting. Follow the instructions provided by the referring doctor and Focus Diagnostics.

Inform the doctor about all prescription medicines, non-prescription medicines, corticosteroids, immunosuppressive therapy, chemotherapy, antibiotics, nutritional supplements, and herbal products. Do not discontinue treatment without medical advice.

Tell the healthcare provider about sarcoidosis, tuberculosis exposure, chronic infection, kidney disease, haematological disease, recent biopsy, cancer treatment, inflammatory symptoms, and previous lysozyme results.

Inform the doctor about symptoms such as persistent cough, breathing difficulty, enlarged lymph nodes, skin lesions, eye inflammation, fever, weight loss, fatigue, recurrent infections, easy bruising, abnormal bleeding, or bone pain. These symptoms require complete medical assessment and are not specific to lysozyme abnormalities.

Maintain normal hydration unless the doctor provides different instructions. Inform the phlebotomist if you have a bleeding disorder, take blood-thinning medicines, or have previously experienced fainting during blood collection.

What Happens During the Test?

A trained phlebotomist cleans the skin over a suitable vein, generally in the arm, and collects a small blood sample using a sterile needle. The procedure normally takes only a few minutes.

After collection, the needle is removed and pressure is applied to the site. Mild discomfort, bruising, tenderness, or minor bleeding may occur. Serious complications are uncommon.

The blood is processed to separate serum. The specimen may require transfer to a suitable transport tube, refrigeration, freezing, or shipment to a specialised referral laboratory. Sample handling follows the requirements of the performing method.

The laboratory measures lysozyme using a validated analytical technique. The report provides a numerical value, unit of measurement, and method-specific reference interval. Results obtained using different analytical methods may not be directly comparable.

Normal Reporting Time

The report for the Lysozyme (Muramidase) test is generally available within 7 to 10 working days. This is a specialised investigation that may require batch processing or analysis at a referral laboratory.

The turnaround time may vary because of specimen transport, testing schedules, quality-control requirements, sample dilution, repeat analysis, or confirmation. Patients should confirm the expected reporting time with Focus Diagnostics.

Who Should Consider the Lysozyme Test?

• Patients undergoing specialist evaluation for suspected sarcoidosis.
• Individuals with confirmed sarcoidosis requiring selected biochemical monitoring.
• Patients with clinical or laboratory findings suggesting monocytic or myelomonocytic leukaemia.
• Individuals undergoing evaluation for another myeloid haematological disorder.
• Patients with granulomatous inflammation requiring supplementary laboratory assessment.
• Individuals with suspected tuberculosis or another infection when ordered as part of a broader evaluation.
• Patients with unexplained high lysozyme-associated renal or electrolyte abnormalities.
• Individuals referred by a pulmonologist, haematologist, rheumatologist, or physician.
• Patients whose previous lysozyme result was elevated and requires specialist follow-up.
• Individuals specifically advised to undergo testing after clinical, imaging, or haematological assessment.

Understanding the Test Results

The result is reported as a numerical lysozyme concentration or activity with a method-specific unit and reference interval. The laboratory's reference range should be used because values can vary with age, method, and assay calibration.

Result Within the Reference Interval: A result within the expected range means that increased serum lysozyme was not detected at the time of testing. It does not exclude sarcoidosis, tuberculosis, leukaemia, or another inflammatory or haematological condition.

Elevated Lysozyme: Increased serum lysozyme may be associated with sarcoidosis, tuberculosis, other granulomatous diseases, monocytic or myelomonocytic leukaemia, selected myeloid disorders, kidney dysfunction, and other inflammatory conditions. The degree of elevation cannot by itself identify the cause.

In a patient with confirmed sarcoidosis, the doctor may compare the result with previous values, symptoms, imaging, pulmonary function, organ-specific tests, and treatment. A change in lysozyme alone should not determine treatment.

In a patient with abnormal blood counts or suspected leukaemia, elevated lysozyme may support monocytic differentiation but does not replace bone-marrow examination, flow cytometry, cytogenetic testing, or molecular classification.

Low Lysozyme: A low value is generally less diagnostically useful and does not independently indicate impaired immunity. The clinical significance depends on the reason for testing and the laboratory method.

If the result is unexpected, the doctor may request repeat testing, complete blood count, peripheral smear, kidney function, liver function, calcium, angiotensin-converting enzyme, inflammatory markers, microbiological studies, imaging, flow cytometry, bone-marrow examination, or biopsy.

Clinical Limitations

Lysozyme is a non-specific marker. It can be elevated in multiple inflammatory, infectious, renal, and haematological conditions. It cannot independently differentiate sarcoidosis from tuberculosis or other granulomatous disorders.

The test has limited specificity for classifying acute leukaemia. Occasional elevations can occur in subtypes without predominant monocytic differentiation. Modern haematological classification requires cellular and molecular testing.

Kidney function can influence serum lysozyme because the protein is filtered and metabolised through the renal system. Reduced kidney function may complicate interpretation.

Corticosteroids, immunosuppressive treatment, chemotherapy, changes in disease activity, and analytical differences may affect serial measurements. Results from different laboratory methods may not be directly interchangeable.

Important Safety Information

Seek prompt medical care for severe breathing difficulty, chest pain, sudden visual changes, severe weakness, high fever, uncontrolled bleeding, confusion, or rapidly worsening symptoms. This laboratory test should not delay emergency assessment.

An elevated lysozyme result does not mean that a patient definitely has sarcoidosis, tuberculosis, or leukaemia. Do not start steroids, antimicrobial medicines, chemotherapy, or other treatment based only on this result.

This information is intended for general education and does not replace diagnosis or advice from a pulmonologist, haematologist, infectious-disease specialist, or other healthcare professional. Always discuss the result with the referring doctor.